3 affordable Houston neighbors rank among America's 10 safest cities

HIGH PRAISE FOR THE 'BURBS

League City, Sugar Land, and Pearland were just crowned among the top 10 safest and most affordable cities to live in the U.S. Photo via Getty Images

Crime may be a concern for some Houstonians, but life is a little more relaxed just beyond the city limits.

Three Houston-area suburbs – League City, Sugar Land, and Pearland – were just crowned among the top 10 safest and most affordable cities to live in the U.S., as declared in a new report by GoBankingRates.

The study, "50 Safest and Most Affordable US Cities To Live In," ranked the largest U.S. cities by population based on their cost of living and crime rate averages. Crime rates were determined based on the number of crimes per 1,000 city residents from the FBI’s Crime Data Explorer in 2022, the year with the most recent available data.

League City proudly landed in the No. 4 spot nationally, thanks to its low property and violent crime rates as well as a high median household income. Sugar Land and Pearland weren't too far behind in the top 10, ranking No. 6 and No. 7, respectively. The report emphasized these suburbs all offer "vibrant cultural scenes" and strong job markets for adults, along with great schools and abundant recreational activities for families to enjoy.

A League City household makes a median income of $117,316 annually, with an average mortgage cost of $2,216 per month, the report found. The total monthly cost of living in the family friendly city adds up to $4,157.

There were a total of 1,497 property crimes reported in the city in 2022, and 126 total violent crimes. For context, the U.S. Census Bureau estimated the population in League City spans more than 116,000 residents in 2023. That means the city's rate for violent crimes is 1.08 per 1,000 residents, and the property crime rate is 12.85 per 1,000 residents, according to the findings.

Sugar Land's median household income is much higher than League City's, at $132,247 per year. However, so were the average mortgage costs ($2,715 per month) and total monthly cost of living ($4,852).

There were 1,745 property crimes and 97 violent crimes reported in Sugar Land in 2022. That would place Sugar Land's property crime rate at 16.16 per 1,000 city residents, and 0.90 violent crimes per 1,000 residents.

Here's how the report breaks down Pearland's cost of living and crime rate statistics:

  • Median household income: $111,123
  • Household average mortgage cost: $2,257
  • Total monthly cost of living: $4,352
  • Property crimes (reported in 2022): 2,152
  • Property crime per 1,000 residents: 17.09
  • Violent crimes (reported in 2022): 117
  • Violent crime per 1,000 residents: .93

Large Texas cities, such as Houston proper, Dallas, Fort Worth, Austin, and San Antonio, were all noticeably absent in the ranking. This is likely because – as most Texans are aware – bigger cities often have higher crime rates and higher costs of living than their outlying suburbs.

"Choosing a family-friendly place to live is a significant decision that involves a balancing act between safety and affordability in any big city," the report said. "Whether you’re a young professional, a growing family or a retiree, finding real estate where you feel comfortable — both physically and financially — is crucial for a high quality of life."

Other Texas cities that were ranked in the top 25 safest and most affordable places to live include El Paso (No. 11), McKinney (No. 15), Frisco (No. 16), Laredo (No. 18), Grand Prairie (No. 21), Plano (No. 22), Carrollton (No. 23), and McAllen (No. 24).

The top 10 safest and most affordable U.S. cities to live in are:

  • No. 1 – Elgin, Illinois
  • No. 2 – Cary, North Carolina
  • No. 3 – Gilbert, Arizona
  • No. 4 – League City, Texas
  • No. 5 – Rochester, Minnesota
  • No. 6 – Sugar Land, Texas
  • No. 7 – Pearland, Texas
  • No. 8 – Meridian, Idaho
  • No. 9 – Broken Arrow, Oklahoma
  • No. 10 – Olathe, Kansas
The full report and its methodology can be found on gobankingrates.com

.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings